Key result
A linear discriminant model correctly classified 81.7% of 'winners' and 21.1% of 'losers' to enoxaparin prophylaxis based on patient characteristics.
Why the study?
What baseline characteristics predict benefit from enoxaparin for VTE prophylaxis in digestive surgery?
Observational (n=445)
What baseline characteristics predict benefit from enoxaparin for VTE prophylaxis in digestive surgery?
A linear discriminant model identified that young, female patients with specific normal-range lab values are most likely to benefit from enoxaparin for VTE prophylaxis after digestive surgery.
Answers are grounded in this paper and cite their sources.
May identify enoxaparin candidates after digestive surgery; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: A total of 826 patients were included in three 'play-the-winner' studies to investigate the safety of prophylaxis against venous thromboembolism in digestive surgery. To characterize patients benefiting from prophylaxis with low-molecular heparin, the 445 patients allocated to enoxaparin were investigated. METHODS: A training set consisting of 292 patients from 2 of the studies was analysed by using a linear discriminant model. The reliability of the results was verified on a test set consisting of 153 patients from the third study. RESULTS: A typical 'winner' was a young patient, preferably female, with serum bilirubin in the lower normal range, combined with body temperature, serum sodium, creatinine, and albumin in the upper normal ranges. By using the discriminant function on the test set, 81.7% of the 'winners' and 21.1% of the "losers' were correctly classified. CONCLUSION: The discriminant function for characterization of winners to enoxaparin was found adequate. No rule was acceptable for characterization of losers.
No takes yet. Share an insight, caveat, or question.
Reiertsen et al. (1996) conducted an observational in Postoperative Venous Thromboembolism in Digestive Surgery (n=445). Enoxaparin was evaluated on Correct classification of 'winners' and 'losers' to enoxaparin using a linear discriminant model. A linear discriminant model correctly classified 81.7% of 'winners' and 21.1% of 'losers' to enoxaparin prophylaxis based on patient characteristics.
Synapse has enriched 10 related papers. Consider them for comparative context: